NEW YORK, Oct 24 – Genomic Solutions said Tuesday its third quarter losses narrowed significantly, beating Wall Street’s expectations by 5 cents.

The company reported pro forma net losses of $869,000, or 3 cents per share, compared with a net loss of $3.9 million, or $1.31 per share, in the year-earlier period, including a $1.2 million non-cash common stock warrant charge. Excluding that charge, third-quarter 1999 losses were 92 cents per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.